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Abstract
Background: New pre-clinical trials in AD mouse models may help to develop novel immunogen-
adjuvant configurations with the potential to avoid the adverse responses that occurred during the
clinical trials with AN-1792 vaccine formulation. Recently, we have pursued an alternative
immunization strategy that replaces QS21 the Th1 type adjuvant used in the AN-1792 clinical trial
with a molecular adjuvant, mannan that can promote a Th2-polarized immune response through
interactions with mannose-binding and CD35/CD21 receptors of the innate immune system.
Previously we established that immunization of wild-type mice with mannan-Aβ28 conjugate
promoted Th2-mediated humoral and cellular immune responses. In the current study, we tested
the efficacy of this vaccine configuration in amyloid precursor protein (APP) transgenic mice
(Tg2576).
Methods: Mannan was purified, activated and chemically conjugated to Aβ28 peptide. Humoral
immune responses induced by the immunization of mice with mannan-Aβ28 conjugate were
analyzed using a standard ELISA. Aβ42 and Aβ40 amyloid burden, cerebral amyloid angiopathy
(CAA), astrocytosis, and microgliosis in the brain of immunized and control mice were detected
using immunohistochemistry. Additionally, cored plaques and cerebral vascular microhemorrhages
in the brains of vaccinated mice were detected by standard histochemistry.
Results: Immunizations with low doses of mannan-Aβ28 induced potent and long-lasting anti-Aβ
humoral responses in Tg2576 mice. Even 11 months after the last injection, the immunized mice
were still producing low levels of anti-Aβ antibodies, predominantly of the IgG1 isotype, indicative
of a Th2 immune response. Vaccination with mannan-Aβ28 prevented Aβ plaque deposition, but
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compared to two groups of control animals of the same age either injected with molecular adjuvant
fused with an irrelevant antigen, BSA (mannan-BSA) or non-immunized mice. Of note, mice
immunized with mannan-Aβ28 showed a trend toward elevated levels of CAA in the neocortex and
in the leptomeninges compared to that in mice of both control groups.
Conclusion: Mannan conjugated to Aβ28 provided sufficient adjuvant activity to induce potent
anti-Aβ antibodies in APP transgenic mice, which have been shown to be hyporesponsive to
immunization with Aβ self-antigen. However, in old Tg2576 mice there were increased levels of
cerebral microhemorrhages in mannan-Aβ28 immunized mice. This effect was likely unrelated to
the anti-mannan antibodies induced by the immunoconjugate, because control mice immunized
with mannan-BSA also induced antibodies specific to mannan, but did not have increased levels of
cerebral microhemorrhages compared with non-immunized mice. Whether these anti-mannan
antibodies increased the permeability of the blood brain barrier thus allowing elevated levels of
anti-Aβ antibodies entry into cerebral perivascular or brain parenchymal spaces and contributed to
the increased incidence of microhemorrhages remains to be investigated in the future studies.
Background
The neuropathological features of Alzheimer's disease
(AD) include neurofibrillary tangles (NFT), deposition of
amyloid-β (Aβ) in senile plaques, and neuronal loss in
affected brain regions [1]. The Aβ is cleaved from the amy-
loid precursor protein (APP) by the β- and γ-secretases [2-
4], and is believed to play an important role in the onset
and progression of AD [5,6]. Accordingly, many of the
strategies currently being proposed as therapies for AD are
aimed at reducing the level of Aβ in the brain, and/or pre-
venting the assembly of this peptide into pathological
forms. One potentially powerful strategy for reducing the
level of Aβ in the brain is immunotherapy, in which anti-
bodies specific for Aβ facilitate the clearance amyloid
deposits and a reduction in other forms Aβ in the brain
parenchyma. Both active and passive Aβ-immunotherapy
significantly decrease amyloid deposits, neuritic dystro-
phy and gliosis in the brain, as well as improve behav-
ioural measures in APP/Tg mice [7-12]. Based on these
and other studies in several animal models, the AN-1792
clinical trial was initiated in patients with mild-to-moder-
ate AD, however the trial was halted during the phase II
portion of the trial when approximately 6% of the AD
patients vaccinated with AN1792 developed meningoen-
cephalitis and in some cases CAA associated haemor-
rhages. The cause of the encephalitis in these patients has
not yet been determined, however speculation has
focused on autoreactive T-cells and the proinflammatory
Th1 type of adjuvant that was used in the clinical trial [13-
16]. Of note, there is only one unconfirmed report about
lymphocyte infiltration detected in the brains of wildtype
mice immunized with Aβ42 formulated in FCA/FIA fol-
lowed by injection with pertussis toxin [17]. In addition
to T cell infiltration into the brain parenchyma, another
participant in the clinical trial developed widespread cor-
tical hemorrhages [16]. Microhemorrhages in the cerebral
vasculature have also been observed in different strains of
very old (21–26 month-old) APP/Tg mice injected weekly
with high doses of anti-Aβ monoclonal antibodies, and
the sites of microhemorrhage have been co-localized with
cerebral vascular Aβ deposits [18-21]. Recently, it was
reported that active immunizations of APP/Tg mice with
fibrillar Aβ42 formulated in a strong conventional adju-
vant, Freund's complete adjuvant system (FCA), could
also increase microhemorrhages in the brains of vacci-
nated animals [22]. Collectively, these adverse events
emphasized the need for further refinement of vaccines
for AD in order to eliminate, or at least attenuate, the
potential adverse events initiated by infiltration of autore-
active T cells and peripheral macrophages, as well as
inflammation-induced cerebral vascular microhemor-
rhages.
Mannan and other polysaccharides are recognized by col-
lectins, such as, Mannose-Binding Lectin (MBL) [23-25],
as well as Mannose Binding Receptors (MBRs) expressed
on dendritic cells, some endothelial cells and macro-
phages [26-29]. After binding to mannan, MBL initiates
the complement pathway via an activation of the MASP-1
& MASP-2 proteases, and is antibody- and C1q-independ-
ent. Therefore, immunization of mice with Aβ peptide
sequences conjugated to mannan should induce comple-
ment activation and C3d opsonization on the Aβ. Moreo-
ver, MBL, which also has opsonic function like
complement C1q (homologue of MBL), binds to comple-
ment receptor type 1 (CR1/CD35) [30] and therefore
stimulates phagocytosis of the conjugated antigen.
Finally, T-cell dependent B-cell immune responses can be
activated not only by simultaneous triggering of BCR and
C' receptor type 2 (CD21), but also by simultaneous trig-
gering of BCR and C' receptor type 1 (CD35) [31,32].
Importantly, different groups have already demonstrated
enhancement of T-helper and B-cell immune responses
against several mannosylated-antigens, including pep-Page 2 of 16
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of C', Aβ-mannan conjugates will be recognized by MBRs
found on dendritic cells, some endothelial cells and mac-
rophages [26-28]. The macrophage mannose receptor
(MMR) and DEC-205 found on dendritic and some
endothelial cells bind multiple carbohydrates [36]. These
receptors significantly enhance phagocytosis of antigens
containing an appropriate carbohydrate, such as mannose
residues. In addition, the receptors can also increase anti-
gen presentation on macrophages and dendritic cells by
100- to 1,000-fold over antigens without carbohydrate
residues. Thus, besides activating complement, Aβ conju-
gated to mannan will also promote phagocytosis and anti-
gen presentation on macrophages and dendritic cells of
the immune system, providing an added benefit from the
conjugation of mannan to Aβ. Notably, under certain con-
ditions, mannosylated antigens induced strong Th2-type
anti-inflammatory responses (production of IL4/IL10
cytokines) with high levels of IgG1 antibodies
[33,34,37,38].
Previously, we generated mannan-Aβ28 conjugate and
demonstrated that immunization of wild-type mice with
this vaccine enhanced the production of IL4 (Th2-type)
cytokine followed by generation of antibodies specific to
the self-Aβ antigen [39]. Here for the first time we tested
the safety and efficacy of mannan-Aβ28 conjugate in
Tg2576 mouse model of AD. We demonstrated that, in
the absence of any conventional adjuvant, mannan-Aβ28
conjugate enhanced the production of Th2-type anti-Aβ
antibodies inhibiting Aβ plaque formation. However, the
mannan-peptide conjugate induced higher levels of
microhemorrhages compared to that in the brains of age-
matched control animals.
Methods
Preparation of mannan-Aβ28 immunoconjugate
Mannan (Saccharomyces cerevisiae, Sigma, MO) was puri-
fied by passage over a Q Sepharose FF column (GE
Healthcare) to remove residual nucleic acid. Mannan was
activated [40] and conjugated to Aβ28 peptide, as previ-
ously described[39]. In brief, a 10 mg/ml solution of man-
nan was activated by addition of the organic cyanylating
reagent 1-cyano-4-dimethylaminopyridinium tetrafluor-
oborate (CDAP) (25 μl/ml, 100 mg/ml in acetonitrile).
After 30 sec, 25 μl/ml of aqueous 0.2 M triethylamine
(TEA) was added. After another 2 min an equal volume of
0.5 M hexanediamine, pH 9, was added and the reaction
allowed to proceed overnight and then dialyzed against
water. The mannan concentration and the free amine con-
tent were determined as previously described [40]. The
amino-mannan was bromoacetylated using NHS bro-
moacetate, and desalted by dialysis. Aβ28 peptide (5.0 mg/
ml) with an N-terminal linker (n-CAGA) sequence syn-
thesized by (Multiple Peptide Systems, San Diego, CA)
was dissolved in 0.15 M HEPES, 2 mM EDTA, pH 7.3, and
the free thiol content determined using Ellman's reagent.
The peptide was combined with the bromoacetylated
mannan at a molar ratio of 30 thiols/100 kDa of carbohy-
drate under a stream of nitrogen. After an overnight reac-
tion, the solution was quenched by the addition of
mercaptoethanol concentrated with an Ultra 4 (10 kDa
cut-off) device (Millipore, MA), and free peptide removed
by gel filtration on a Sepharose 12 column (GE Health-
care, NJ), equilibrated with 0.1 M HEPES, pH 8. The void
volume peak was pooled. The peptide content was deter-
mined from the UV spectrum and its calculated extinction
coefficient. The final product contained 50 μM peptide at
a ratio of 5 moles of peptide per 100 kDa of mannan for-
mulated in PBS.
To generate a control mannan-antigen conjugate, mannan
was coupled with BSA via a thiol-ether linkage as
described for Aβ28 peptide except that the reaction was
quenched with ethanolamine before gel filtration on a
S300HR column (GE Healthcare, NJ). The peak tube from
the void volume was assayed by the Bradford method
using BioRad protein reagent, with BSA as the standard.
Finally, biotinylated mannan was prepared by reaction of
biotin-NHS with the amino-mannan, and un-reacted
biotin was removed by gel filtration.
Immunization of mice and detection of anti-Aβ and anti-
mannan antibodies
Based on our results with wild-type mice [39], we immu-
nized young 4–4.5 mo-old Tg2576 (APPsw) mice [Tg
(HuAPP695.K670N/M671L) 2576] [41,42] without pre-
existing AD-like pathology [43], (n = 8, 3 males, 5
females), six times biweekly with 10 μg/mouse of man-
nan-Aβ28 conjugate, subcutaneously (s.c.). Control mice
of the same age were either injected 6 times s.c. with man-
nan-BSA conjugate (n = 6, 3 males, 3 females), or
remained non-immunized (n = 5, 2 males, 3 females). We
collected sera on the 9th day after the last injection, or at
the end of the resting period (~11 months), and examined
the humoral immune responses by ELISA. Anti-Aβ anti-
bodies and their isotypes were detected in individual sera
as previously described [39,44-46]. Of note, concentra-
tions of anti-Aβ antibodies were calculated using a stand-
ard curve generated with 6E10 monoclonal antibody
(Signet, MA). Also, using a similar ELISA technique we
detected the titers of anti-mannan antibodies, although in
these experiments streptavidin pre-coated plate wells
(Express Biotech International, MD) were coated with 2
μg/ml biotinylated mannan as recommended by manu-
facturer before addition of immune or control sera.
Dot blot assay
Binding of anti-Aβ28 antibody to different forms of Aβ42
peptide was demonstrated as described [47]. Briefly, 1 μlPage 3 of 16
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After blocking and washing, the membranes were probed
with sera from mice immunized with mannan-BSA, man-
nan-Aβ28 (1 μg/ml), anti-Aβ 20.1 monoclonal (1 μg/ml)
antibody, or rabbit A11 polyclonal (1 μg/ml) antibody
previously described by [48]. The membranes were incu-
bated with appropriate HRP-conjugated anti-mouse
(1:2000) or anti-rabbit (1:2000) antibody (Santa Cruz
Biotechnology, CA). Blots were developed using Luminol
reagent (Santa Cruz Biotechnology, CA) and exposed to
Kodak X-Omat AR film.
Immunohistochemistry
After the termination of the study, we obtained the brains
of experimental and control mice (~18–18.5 months) and
analyzed the impact of active immunization with man-
nan-Aβ28 on neuropathological changes as we previously
described [47,49,50] Briefly, mice were halothane-anes-
thetized, perfused with PBS prior to removing the brains.
Brains were fixed (4% paraformaldehyde, 48 hrs), and
brain tissues were sectioned (40 μm thick) and stored at
4°C (PBS with 0.02% sodium azide). Staining of dupli-
cates of coronal sections of experimental and control
mouse brains, collected from 3 different planes of the
brain about 1 mm apart, with monoclonal anti-Aβ40 or
Aβ42 (Signet, MA) as we described [49].
The quantitative analysis of CAA was made as described
by [51]. Briefly, CAA score (based on frequency and sever-
ity) was quantified on the sections immunostained with
anti-Aβ40 throughout the neocortex. Six sections from
each brain in the groups of mice immunized with man-
nan-Aβ28, mannan-BSA or non-immunized animals were
analyzed. CAA frequency was calculated by counting the
total number of Aβ-positive vessels in the set of sampled
sections, while CAA severity was assessed using three
severity grades: grade 1, Aβ immunoreactivity confined
strictly to the vessel wall; grade 2, Aβ immunoreactivity in
and around vessel wall with focal infiltration of the amy-
loid in the neuropil; and grade 3, extensive infiltration of
amyloid into the neuropil with a complete amyloid coat
around the vessel. The mean for all vessels was taken as
CAA severity, and final CAA score was calculated by mul-
tiplying CAA frequency with CAA severity. All of the quan-
titations were done on both hemispheres by two
independent investigators and yielded similar results.
Binding of the pooled immune sera from the group of
mice immunized with mannan- Aβ28 to the 50 μm brain
section of formalin-fixed cortical tissue of a 75-year-old
woman with neuropathological and behavioural patterns
typical to severe AD, was done as we described previously
[45,47]. To demonstrate the specificity of binding of anti-
Aβ28 antibodies to the brain tissue we blocked antisera
from immune mice with the Aβ1–15 peptide at 5 μM con-
centration as described [47].
For detection of astrocytosis, we used cow glial fibrillary
acidic protein, GFAP (DAKO, Denmark). To detect micro-
gliosis, we used anti-mouse CD45 (LCA, Ly-5, Pharmin-
gen, CA). Anti-C1q and anti-C3b antibodies (eBioscience,
CA) were used to detect activation of complement as pre-
viously described [52]. Infiltration of T cells was analyzed
using anti-CD3-ε (Santa Cruz Biotechnology, CA) anti-
body. The tissues from all animals within a given experi-
mental group were processed in parallel. Hydrogen
peroxide-quenched and blocked sections were incubated
with primary antibody overnight at 4°C. Sections were
then washed and incubated with appropriate biotinylated
secondary antibodies against corresponding species. Col-
our developed via ABC and DAB (3,3'-diaminobenzidine)
substrate kits (Vector, CA). Images of the immunostaining
were captured using a Sony high-resolution CCD video
camera (XC-77), and quantification of staining was per-
formed using NIH image 1.59b5 software. For every ani-
mal, eighteen images (525 × 410 μm each) of the frontal
parietal region in the cortex area of 2 adjacent sections
were captured with 20× objective. Samples consisted of
nine images from the superficial layer and the remaining
nine from the deep layer. NIH imaging was used to ana-
lyze the area occupied by amyloid plaques, as well as
CD45- and GFAP-immunoreactivity. The threshold for
the detection of immunoreactivity was established and
then held constant throughout the image analysis. Addi-
tionally, we performed a visual inspection of hippocam-
pal and cortical regions of all stained sections in a blinded
fashion (observer had no knowledge of the treatment
group); a mean semi-quantitative score was independ-
ently determined for each slide by 2 observers.
Histochemistry
Determination of cored plaques was accessed using Thio-
flavin-S (ThS) according to a standard protocol from the
IBAD, UCI. Briefly, sections from immunized and control
animals were mounted on Vectabond-coated slides (Vec-
tor Labs, CA). Sections were then washed with Tris buffer
(0.1 M Tris buffered saline at pH 7.5) and stained with
0.5% ThS (Sigma, MO) in 50% ethanol for 10 min.
Finally, sections were washed in 50% ethanol, and twice
in Tris buffer, then dried and coverslipped with Vectash-
ield (Vector Labs, CA). ThS-positive plaques were counted
by visual inspection of cortical and hippocampal regions
of all stained sections in a blinded fashion; a mean semi-
quantitative score was independently determined for each
slide by 2 observers.
Determination of microhemorrhages was performed
using Prussian blue staining of ferric acid according to a
standard protocol from IBAD, UCI. Briefly, duplicates ofPage 4 of 16
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brains, 40 μm thick, collected from 3 different planes of
the brain (about 1 mm apart), were mounted on
Vectabond coated slides (Vector Labs, CA) and stained
with Prussian blue working solution, a mixture of freshly
made 5% Potassium hexacyanoferrate (II) trihydrate, and
5% hydrochloric acid (all from Sigma, MO). After 30 min
all sections were rinsed in water, counterstained with
Nuclear Fast Red (Sigma, MO), dehydrated and covered
using DPX (BDH Laboratory Supplies, England). The
hemorrhage profiles (hemosiderin stain) were counted by
two independent observers, and the average number of
Prussian blue-positive deposits was calculated for each
brain section.
For detection of co-localization of Aβ accumulation and
complement markers in vasculature we used combination
of two methods described above. First, sections were glass
mounted, peroxidase-quenched and stained with anti
C1q and C3b antibodies (eBioscience, CA) followed by
biotinylated secondary antibodies and streptavidin-Alexa
Fluor 555 (Thermo Fisher Scientific, IL). After that, ThS
staining was performed as described above. Confocal
images were collected on an Olympus IX70 inverted
microscope and a BioRad Radiance 2000 Laser Scanning
System using 70× objective for image analysis.
Statistical Analysis
To assess the differences in antibody titers, plaque areas,
glial immunoreactivity, frequency of microhemorrhages
and CAA in experimental mice versus the control groups,
a two-tailed Students's t-tests were performed using Graph
Pad Prism 3.03 software.
Results
Mannan-Aβ28 immunoconjugate induced potent anti-Aβ 
antibody responses in the Tg2576 mouse model of AD
Previously, we have demonstrated that 10 μg of human
mannan-Aβ28 peptide conjugate enhanced Th2 type anti-
Aβ antibody production in wild-type mice[39]. In the cur-
rent study we first analyzed the immunogenicity of man-
nan-Aβ28 immunoconjugate in the Tg2576 mouse model
of AD in which Aβ28 is a self-antigen. After six biweekly
immunizations with the same low dose (10 μg) of man-
nan-Aβ28 antigen, 5 out of 8 Tg2576 mice generated
robust anti-Aβ antibody production, whereas the remain-
ing mice expressed less than 5 μg/ml of antibodies (Figure
1A). Average anti-Aβ antibody concentrations were 10.4
μg/ml, equal to titers of ≥ 1:10,000. The humoral immune
response generated by the mannan-Aβ28 immunogen was
long lasting since the anti-Aβ antibody concentration
remained readily detectable (0.8 μg/ml or approximately
a titer of ≥ 1:800) in vaccinated animals that were held
free of immunizations for 11 months (Figure 1A). Anti-
body isotyping can be used as an indirect measure of the
contribution of Th1 (IgG2a) and Th2 (IgG1) cytokines to
the humoral response[53]. Additionally, the subclass of
anti-Aβ antibodies may correlate with their therapeutic
potential[11,54]. Thus, we measured the production of
IgG1, IgG2ab, IgG2b, and IgM anti-Aβ antibodies in the
sera of vaccinated Tg2576 mice, demonstrating that man-
nan-Aβ28 induced predominantly IgG1, although two
mice also produced significant amount of IgM antibody
(Figure 1B). Interestingly, the isotypic profile of anti-Aβ
antibodies was similar at 9 days and 11 months after the
last boost (Figure 1B), and the ratios of IgG1 to IgG2ab
antibody in these mice were 8.2 and 5.25, respectively.
Thus, immunization with the Aβ28 immunoconjugate
induced long-lasting therapeutically potent anti-Aβ anti-
bodies in Tg2576 mice, and the humoral immune
response was Th2-polarized, similar to the observations
after the conjugation of mannan with other peptide
immunogens [33,37,38] or immunizations of wildtype
mice with mannan-Aβ28[39].
Mannan was previously shown to be a weak T-independ-
ent antigen, however because the mannan was conjugated
to a peptide (Aβ) or a protein (BSA), both of which con-
tain T helper cell epitopes that can be used to promote the
production of anti-mannan antibodies, we analyzed the
antibody response to mannan induced by immunizations
with mannan-Aβ28 or mannan-BSA conjugates. As we
expected, both groups of mice induced only low titers of
anti-mannan antibodies at day 9 after the last boost (Fig-
ure 1C). The anti-mannan antibodies were of the IgG and
IgM isotypes in mice immunized with mannan-Aβ28 and
predominantly of IgG isotypes in mice immunized with
mannan-BSA (Figure 1D). It was not surprising that both
immunoconjugates induced IgG anti-mannan antibodies
because Aβ28 [44] and BSA possess T helper epitope/s that
make mannan-peptide/protein conjugate a T-dependent
antigen.
In the light of recent data that oligomeric forms of Aβ42
peptide are the most toxic forms, we analyzed the binding
ability of immune and control sera to Aβ monomers, oli-
gomers and fibrils by a dot blot assay. Sera from mannan-
Aβ28 immunized, but not from mannan-BSA immunized
mice, bound to all forms of Aβ42, although binding was
better to the monomeric and oligomeric forms than to
fibrillar Aβ42 (Figure 1E). We also demonstrated that
immune sera bound to Aβ plaques in the brain tissue
from an AD clinical case. This binding was specific since
pre-incubation of sera with the Aβ1–15 peptide resulted in
its complete inhibition (Figure 1F).
Immunization with mannan-Aβ28 inhibits AD-like amyloid 
pathology in the brain
Next, we analyzed the extent of AD-like pathology in
brains of vaccinated Tg2576 mice (18–18.5 months old).Page 5 of 16
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with mannan-BSA, or non-immunized group of animals.
Image analysis of anti-Aβ40 and anti-Aβ42 antibody-
stained parietal cortical sections demonstrated a signifi-
cant reduction of amyloid plaques in brains of mice vacci-
nated with mannan-Aβ28 compared with similar brain
staining of non-immunized mice (Figure 2) or animals
injected with mannan-BSA (data not shown). While stain-
ing with anti-Aβ40 and anti-Aβ42 antibodies detected both
cored and diffuse plaques, ThS binds only to cored amy-
loid deposits. Therefore, we compared image analyses
with ThS staining of parietal cortical brain sections from
Mannan-Aβ28 immunoconjugate induces potent levels of anti-Aβ and low levels of anti-mannan antibodies in Tg2576 miceFigure 1
Mannan-Aβ28 immunoconjugate induces potent levels of anti-Aβ and low levels of anti-mannan antibodies in 
Tg2576 mice. A. Vaccinated mice 7–7.5 months of age produced on average 10.4 μg/ml of anti-Aβ antibodies (approximate 
titers ≥ 1:10,000) after 6 immunizations. At termination, when mice reached 18–18.5 months of age they still produced low 
levels of anti-Aβ antibodies (0.8 μg/ml or approximate titers ≥ 1:800). Noteworthy, mice immunized with mannan-BSA did not 
produce detectable levels of anti-Aβ antibodies (data not shown). B. Mannan-Aβ28 induced primarily IgG1 isotype antibodies, 
indicative of a Th2 type humoral immune response before resting period (sera were collected on 9th day after the last boost) 
and after resting period (sera were collected after 11 months). One vaccinated mouse also induced high level of IgM anti-Aβ 
antibodies. C. After 6 injections vaccinated mice produced low titers of anti-mannan antibodies. Of note, the titers of anti-man-
nan antibodies dropped dramatically during the intervening 11 months following the final injection (data not shown). (D). Man-
nan-Aβ28 as well as mannan-BSA induced only low levels of anti-mannan antibodies predominantly of IgG and IgM isotypes in 
mice immunized with mannan-Aβ28, and IgG isotypes for mice immunized with mannan-BSA. E. Anti-Aβ28 antibodies bind to all 
species of Aβ42 peptide. One μl of Aβ42 fibrils, oligomers and monomers (45 μM each) were applied in duplicate to a nitrocel-
lulose membrane and probed with sera from mannan-BSA immunized mice (control), sera from mice immunized with mannan-
Aβ28, anti-Aβ 20.1 monoclonal antibody and rabbit A11 antibody shown to bind oligomeric forms of Aβ42. (F). Binding of 
immune mannan-Aβ28 sera to the AD brain section. Binding of antisera was blocked by Aβ1–15 peptide. Original magnification, 
20×, scale bar = 100 μm.Page 6 of 16
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actively immunized 11 months earlier with the mannan-
Aβ28 conjugate had significantly reduced depositions of
cored amyloid plaques (Figure 2D). A similar reduction in
Aβ40 and Aβ42 amyloid burden, as well as cored plaques
was observed in the hippocampus of vaccinated mice
compared with control non-immunized animals (Figure
2A). Of note, we observed no changes in Aβ depositions
by immunohistochemistry or histochemistry in the brains
of mice immunized 6 times with mannan-BSA compared
to non-immunized control (data not shown). Collec-
tively, these results demonstrate that the mannan-Aβ28
immunogen induced therapeutically potent anti-Aβ anti-
bodies, predominantly of the IgG1 isotype, that effectively
reduced the deposition AD-like plaque pathology in 18–
18.5 months old Tg2576 mice.
Immunizations with mannan-Aβ28 reduced glial activation 
in brains of Tg2576 mice
It was previously reported that following active and pas-
sive Aβ-immunotherapy, microglia activation in brains of
aged APP/Tg mice was attenuated [55-59]. In the current
study, we investigated the relationship between a reduc-
tion in fibrillar amyloid deposition and the state of micro-
glial activation in the brains of Tg2576 mice. After eleven
months mannan-Aβ28 vaccination there was significantly
less microglia activation as detected both in the frontal
cortex and in the hippocampus using anti-CD45 antibody
Vaccination with mannan-Aβ28 attenuates amyloid deposition in the cortical and hippocampal regions of brainsFigure 2
Vaccination with mannan-Aβ28 attenuates amyloid deposition in the cortical and hippocampal regions of 
brains. A. Representative images of hippocampal region from non-immunized controls and mice immunized with mannan-Aβ28 
showing reduction of Aβ42 and Aβ40 amyloid burden or cored amyloid plaques. Aβ deposits were stained with anti-Aβ42, anti-
Aβ40 antibodies, and with ThS. Original magnifications, 5× for anti-Aβ42/40 staining and 4× for ThS (scale bars = 200 μm). B, C, 
D. Image analysis of Aβ42 (B), Aβ40 (C) staining, and number of ThS-positive cored plaques (D) in cortex of 18–18.5 mo old 
Tg2576 non-immunized mice and mice immunized with mannan-Aβ28. Vaccinated mice showed significant reduction in Aβ42 (P 
= 0.0075), Aβ40 (P = 0.0103) burden, and in number of ThS-positive cored plaques (P = 0.0019) compared to that in non-immu-
nized control group. Bars represent mean ± SE from n = 5 in the group of non-immunized mice, and n = 8 in the group of mice 
immunized with mannan-Aβ28.Page 7 of 16
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fact, in the hippocampus areas of vaccinated mice we
detected only a few cells weakly stained for CD45, while
similar brain areas of the age-matched non-immunized
Tg2576 mice (Figure 3C) or mannan-BSA (data not
shown) were stained intensively for CD45.
It was previously shown that Aβ immunotherapy may
reduce neuritic dystrophy and astrogliosis, along with
reversing memory deficits in mouse models of AD
[11,60,61]. To determine the role of vaccination with
mannan-Aβ28 in the reduction of astrocytosis, we stained
brains of vaccinated and non-immunized control mice
with anti-GFAP antibody. Image analyses of parietal corti-
cal tissues demonstrated that brains of vaccinated mice
were stained less robustly than those of control animals.
Although, there was a trend toward less stimulation of
astrogliosis, it did not reach significance in the cortex (Fig-
ure 3B), a similar trend was also observed in the hippoc-
ampus region of brains from vaccinated mice (Figure 3D).
Vaccination with mannan-Aβ28 immunoconjugate induced 
microhemorrhage
Previous studies have shown that passive immunotherapy
with high doses of anti-Aβ antibodies may induce micro-
hemorrhage in aged APP/Tg mice [18,21]. More recently,
it was reported that multiple (10 times) immunizations of
APP+PS1 mice with high doses of fibrillar Aβ42 formu-
lated in conventional adjuvant (FCA/FIA) could also
increase microhemorrhage in 20 months old mice [22].
Interestingly, in PDAPP mice passive vaccination with
anti-Aβ antibodies cleared vascular amyloid, but high
doses of antibodies induced microhemorrhages that are
limited to focal perivascular sites [62]. Here, we analyzed
microhemorrhage in 18–18.5 months-old Tg2576 mice,
vaccinated with low doses of mannan-Aβ28, for 11
months prior to sacrifice, by hemosiderin staining with
Effects of vaccination with mannan-Aβ28 on microglial and astrocyte activation in Tg2576 miceFigure 3
Effects of vaccination with mannan-Aβ28 on microglial and astrocyte activation in Tg2576 mice. Image analysis of 
cortical sections performed after staining with anti-CD45 (A) and anti-GFAP (B) antibodies of brain sections from non-immu-
nized controls and mice immunized with mannan-Aβ28. Significantly less microglial activation (P = 0.0003) and lower level of 
astrocytosis (P = 0.3263) were detected after immunization with mannan-Aβ28 compared to non-immunized control mice. 
Representative pictures of staining with anti-CD45 (C) and anti-GFAP (D) antibodies showing a decrease in immunoreactivity 
in hippocampal areas of brain sections of mice immunized with mannan-Aβ28 versus control non-immunized mice. Original 
magnifications: 5×, scale bar = 200 μm.Page 8 of 16
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the brains of mannan-Aβ28 vaccinated animals were com-
pared with that in the brains of control age-matched ani-
mals immunized with mannan-BSA, or non-immunized
mice. We observed low numbers of microhemorrhage in
both non-immunized and mannan-BSA injected control
aged mice. In contrast, following vaccination with man-
nan-Aβ28, we detected significantly (P < 0.001) higher
numbers of microhemorrhage (Figure 4A). Additionally,
we observed larger microhemorrhage in mice vaccinated
with mannan-Aβ28 (Figure 4B, C, D), than in mannan-
BSA (Figure 4E, F), or non-immunized control animals
The incidence and severity of vascular microhemorrhages increased following mannan-Aβ28 immunizationsFigure 4
The incidence and severity of vascular microhemorrhages increased following mannan-Aβ28 immunizations. A. 
Quantification of Prussian blue staining based on the total number of positive profiles per section for mice injected with man-
nan-Aβ28, mannan-BSA, or non-immunized group. The levels of microhemorrhages were increased in vaccinated Tg2576 mice 
(n = 8) to 6.81 ± 2.6 compared to that of 2.31 ± 0.84 in mice immunized with mannan-BSA (n = 6), and 2.07 ± 0.58 in non-
immunized animals (n = 5). *** Indicates P < 0.001. B-G. Examples of microhemorrhage severity in the brain sections of mice 
injected with mannan-Aβ28 (B, C, D), mannan-BSA (E, F), or non-immunized animals (G). B. A focal microhemorrhage (arrow) 
at the cortical-subcortical junction, below the gray-white matter border, lateral to hippocampus. C. Representative images of 
the Prussian blue-positive blood vessels (arrows) most prominent in the meningeal, superficial parenchymal and cortical ves-
sels. D. A focal hemorrhage in the area of anterior commissure. E. A single microhemorrhage (arrow) in the white matter 
region. F. Microhemorrhage-free cortical and leptomeningeal areas. G. Two microhemorrhages (arrows) in the cortical and 
white matter regions. Original magnification, 10×, scale bar = 100 μm.Page 9 of 16
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Aβ-immunizations resulted in reduction of amyloid dep-
osition, but also increased incidence of microhemorrhage
associated with increased CAA in humans [14] and APP/
Tg mice [20]. Thus, we undertook a semi-quantitative
analysis of the CAA in the cortical brain sections of mice
injected with mannan-Aβ28, mannan-BSA, or non-immu-
nized animals. CAA score was calculated based on the fre-
quency and severity of the Aβ immunoreactivity confined
strictly to the vessel wall, around vessel wall with focal
infiltration of the amyloid in the neuropil, or extensively
infiltrated into the neuropil with a complete amyloid coat
around the vessel as it is shown in Figure 5A, B, C. Using
this approach we calculated CAA in neocortical areas of
experimental and control animals and demonstrated that
the CAA score was almost equal in mice vaccinated with
mannan-Aβ28, mannan-BSA or non-immunized control
(P > 0.05, Figure 5D). Of note, we did not quantitate CAA
in the meninges in this study, because the above men-
tioned standard Aβ burden measurements made in the
parenchyma and normalized to brain region were not
applicable to the meningeal location of vascular Aβ
deposits.
Since the activation of the complement cascade by anti-
body-Aβ immune complexes at sites of cerebral amyloid
angiopathy (CAA) may be one possible cause of microhe-
morrhage, it was of interest to analyze the opsonization of
sites of microhemorrhage with C1q and C3 proteolytic
fragments, C3b, complement components in mice immu-
nized with mannan-Aβ28. We detected the accumulation
of these complement proteins in the cerebral vasculature
Semi-quantitative analysis of CAA in the neocortex areas of animals immunized with mannan-Aβ28, mannan-BSA, or non-immu-nized miceFigure 5
Semi-quantitative analysis of CAA in the neocortex areas of animals immunized with mannan-Aβ28, mannan-
BSA, or non-immunized mice. A, B, C. Examples of CAA severity grades: grade 1, Aβ immunoreactivity confined strictly 
to the vessel wall (A); grade 2, Aβ immunoreactivity in and around vessel wall with focal infiltration of the amyloid in the 
neuropil (B); grade 3, extensive infiltration of amyloid into the neuropil with a complete amyloid coat around the vessel (C). 
Original magnification 20×, scale bar = 50 μm. D. The CAA score detected in the neocortex of mice vaccinated with mannan-
Aβ28, was similar to that detected in neocortex of animals injected with mannan-BSA or non-immunized mice (P > 0.05). Bars 
represent mean ± SE from n = 5 in the group of non-immunized mice, n = 6 in the group of mannan-BSA immunized group, and 
n = 8 in the group of mice immunized with mannan-Aβ28.Page 10 of 16
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mannan-BSA (Figure 6A). In the meningeal vessels, in the
group of mannan-Aβ28 immunized animals we have dem-
onstrated partially cleared ThS-stained vascular fibrillar
Aβ deposits abundantly decorated with C1q component
of complement, while only trace amount of C1q was co-
localized with compact Aβ load in the meninges of man-
nan-BSA immunized group, and practically none of the
C1q was detected in the Aβ-laden meninges of non-
immunized animals (Figure 6B). The similar co-localiza-
tion pattern was shown for C3b component of comple-
ment (data not shown).
Discussion
Anti-Aβ immunotherapy is one strategy for the inhibi-
tion/reduction of soluble and insoluble amyloid-β depos-
its that likely play a causal role in the onset and
progression of AD [5,6]. Several pre-clinical studies with
mouse models of AD have demonstrated the ability of Aβ
vaccination to prevent amyloid deposition in the brain.
Thus, active immunization with Aβ [7,63], as well as pas-
sive immunization intraperitoneally [11], or direct to the
brain application of anti-Aβ antibodies[64], resulted in
reduction of the amyloid burden in the brain. Impor-
tantly, active immunizations prevented cognitive decline
[8,9], and passive immunizations were shown to reverse
the memory loss in aged Tg2576 mice [65]. While these
and other studies did not report any adverse events in AD
mouse models immunized with fibrillar Aβ42, data from
the AN-1792 vaccine trial suggest that the adverse reac-
tions to Aβ42-immunotherapy were not due to the
humoral antibody response, but rather to the cell-medi-
ated autoimmune response, possibly exacerbated by the
reformulation of adjuvant, QS21 supplemented with
polysorbate-80, which induced a Th1 type immune
response in patients that received the AN1792 vaccine
[13-16,63,66-69]. Thus, the goal of this pre-clinical study
was to employ a molecular adjuvant, mannan, that
induces a Th2-type humoral immune response specific to
Aβ peptide, and test the efficacy of vaccination on AD-like
pathology in aged Tg2576 mice.
Previously, mannan was shown to enhance both humoral
and cellular immunity against various immunogens con-
Immunostaining of neocortex for C1q and C3b components of complement, and concomitant staining of meninges for C1q and ThSFigure 6
Immunostaining of neocortex for C1q and C3b components of complement, and concomitant staining of 
meninges for C1q and ThS. A. Representative images of cortex areas of coronal brain sections of mice immunized with 
mannan-Aβ28 or mannan-BSA, immunostained with antibodies specific for C1q and C3b components of complement. Original 
magnification, 20×, scale bar = 50 μm. B. Representative images of colocalization of vascular fibrillar Aβ detected with ThS 
(green) with C1q component of complement (red) in the meninges of coronal brain sections of mice immunized with mannan-
Aβ28, mannan-BSA or non-immunized animals. Original magnification, 70×.Page 11 of 16
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ute to the adjuvant properties of mannan conjugates,
including activation of complement, enhancing uptake
and presentation of the conjugated antigen, as well as by
providing a stronger signal to antigen-specific B cells by
simultaneous triggering of B-cell receptors and CD21/
CD35 molecules [26-28,31-35,70-75]. Notably, under
certain conditions mannan was shown to induce predom-
inantly Th2 polarized anti-inflammatory immune
responses to a conjugated non-self peptides
[33,34,37,38], a response which would presumably be
beneficial to an anti-Aβ vaccine. We previously reported
that Aβ42 possesses B and T cell antigenic epitopes, both of
which are contained within the Aβ28 peptide in mice [44].
In addition, our previous studies in wild-type mice using
mannan conjugated to Aβ28 peptide was able to induce
potent and highly polarized Th2 phenotype anti-Aβ anti-
body responses [39]. In the current study, we immunized
anti-Aβ hyporesponsive Tg2576 mice with mannan-Aβ28
conjugate prior to the onset of amyloid plaque pathology
in the brains of Tg2576 mice [43,76]. Mice were immu-
nized six times with low doses (10 μg per mouse) of man-
nan-Aβ28 conjugate and the titer of anti-Aβ antibodies
were assessed by ELISA. The antibodies induced by the
mannan-Aβ28 conjugate were predominantly of the IgG1
isotype and elevated titers were maintained for 11 months
without further immunizations (Figure 1A, B). Thus, we
demonstrated that our mannan-Aβ28 immunoconjugate
induced long-lasting and Th2-polarized anti-Aβ humoral
immune responses in Tg2576 mice in the absence of a
conventional adjuvant, such as alum or CFA. The humoral
immune response induced by mannan-Aβ28 was similar
to that reported after multiple injections of 5 to 10 times
higher doses of fibrillar Aβ42 formulated in strong Th1 or
Th2 conventional adjuvants [7,8,44,77-79].
We examined the effect of mannan-Aβ28 vaccination on
the neuropathology in 18–18.5 months old mice, and
showed a significant reduction in both the Aβ40 and Aβ42
burden, as well as in the number of ThS positive cored
plaques in the parietal cortical and hippocampal regions
(Figure 2) of the brains from mice immunized 11 months
earlier. Of note, previously we demonstrated that Aβ load
was significantly reduced in the brains of Tg2576 mice
with a high concentration of serum anti-Aβ1–11 antibody
(>50 μg/ml), whereas moderate concentration (5–50 μg/
ml) of this antibody resulted in a trend toward a reduction
in Aβ deposits, however it did not reach significance [49].
In the current study antibody specific to Aβ28 even at a
moderate concentration (Figure 1A) significantly reduced
both Aβ40 and Aβ42 deposits. This difference in potency of
anti-Aβ antibody may be due not only to the different
antigen configurations, but also to the starting point of
immunization. More specifically, immunization with
mannan-Aβ28 was started in mice without pre-existing
pathology (preventive vaccination strategy), whereas in
previous study [49] immunization was initiated in mice
with established AD-like pathology (therapeutic vaccina-
tion strategy). Of note, we did not detect any CD3-posi-
tive T cells in the brains of mice immunized with mannan-
Aβ28 (data not shown). Thus, inhibiting Aβ deposition in
immunized Tg2576 mice was not associated with any
adverse events, except for the increase in microhemor-
rhages.
The first two case reports from the AN-1792 clinical trial
both reported meningoencephalitis with lymphocyte
infiltration in the brain [15,16]. Additionally, the third
case report demonstrated increased CAA without clinical
presentation of meningoencephalitis, however there was
noticeable perivascular T cell infiltration [14]. It is worth
mentioning, that a high degree of CAA typically indicates
that hemorrhages are present in the brain [80,81]. How-
ever, only the case report from an AD patient from the Bar-
celona cohort of the AN-1792 trial found fully developed
hemorrhages [16]. The data on anti-Aβ immunotherapy
in experimental mouse models of AD are somewhat dif-
ferent. Normally, rodents do not develop Aβ-CAA, except
several APP transgenic mice models, including aged
Tg2576 mice developing vascular amyloid in addition to
the significant parenchymal amyloid [82,83]. Impor-
tantly, several studies with aged APP/Tg mice reported cer-
ebral vascular microhemorrhages after passive transfer of
high doses of anti-Aβ antibodies [18,20,84]. Additionally,
it was shown that 3D6 antibody specific to N-terminal
region of amyloid, but not antibody against Aβ16–23 (266)
prevented or cleared vascular Aβ in a dose-dependent
manner, but high concentration of this antibody was asso-
ciated with microhemorrhages in focal perivascular sites
[62]. Recently, it was reported that active immunizations
with a high dose of fibrillar Aβ42 plus CFA/IFA also
increased microhemorrhage in aged APP/Tg mice [22].
However, only one study reported meningoencephalitis
in an APP/Tg mouse model passively immunized with
repeated injections of high doses of monoclonal anti-Aβ
antibodies (1 mg within 16 days). Although only 1 out of
21 experimental mice were affected, the authors nonethe-
less suggested that an inflammatory mechanism might be
triggered by antibody binding to cerebral CAA, which in
turn may enhance activation of autoreactive T cells, or
lead to local disruption of the BBB [85]. Accordingly, in
the current study we sought to investigate whether immu-
nization with a mannan-Aβ28 conjugate might induce
infiltration of T cells or increase the incidence of microhe-
morrhages, and CAA. While an examination of the brains
did not reveal meningoencephalitis induced by the pres-
ence of T lymphocytes (data not shown), we observed an
increased incidence and the severity of microhemorrhages
in Tg2576 mice vaccinated with mannan-Aβ28 (Figure 4).
CAA-associated microhemorrhage in aged APP/Tg mice,Page 12 of 16
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for passive immunization [21], implicating the potential
harmful effect of mannan as the trigger of adverse vascular
events. Thus, we attempted to demonstrate CAA-associ-
ated microhemorrhages in vaccinated animals with anti-
Aβ antibodies. We have started with examination the
meningeal and cortical vascular Aβ burden, because simi-
lar to human vascular Aβ, in mice it is first detectable
within leptomeninges, followed mostly by cortical, hip-
pocampal and thalamic areas [86,87]. By 12 months of
age, Aβ deposits in Tg2576 mice are present in the walls of
leptomeningeal and cortical blood vessels, and at 15
months, the percentage load of Aβ-CAA in these areas is
about 1.46% [88]. As mice in our study approached 18
mo of age, the CAA score in neocortex appeared to be sim-
ilar in all groups of experimental and control mice (Figure
5D). Of note, in this study we had not quantified the dif-
ference in the leptomeninges of experimental animals pre-
cisely, due to non-applicability of the standard percentage
area measurements of Aβ made in parenchyma and nor-
malized to brain region to the measurements of the
meningeal location of vascular Aβ deposits.
Although the perivascular macrophages express high lev-
els of mannose receptors [29], it is unlikely that mannan
fused with Aβ28 could cross the BBB and activate these
cells. Of note, infiltration of perivascular macrophages
has been detected predominantly in gray matter, with the
corpus callosum having very few cells, although substan-
tial microhemorrhages in our study were detected among
other areas, both in gray matter and in corpus callosum.
In addition, immunization with mannan-BSA did not ele-
vate the level of hemorrhages compared with low profiles
observed in non-immunized mice (Figure 4).
Notably, titers of the anti-mannan antibodies in mannan-
BSA group were higher than that in mice vaccinated with
mannan-Aβ28 (Figure 1C). Although these data indicate
that anti-mannan antibodies did not contribute directly to
the adverse cerebral vascular events, it is possible that they
may contribute to an increase in BBB permeability,
thereby increasing access of anti-Aβ antibody to perivascu-
lar and parenchymal spaces in mice vaccinated with man-
nan-Aβ28. Importantly, we previously demonstrated that
mannan-Aβ28 or Aβ28 alone did not induce microhemor-
rhage in the brains of wild-type mice [39].
Thus, we hypothesize that a potential cause for the inci-
dences of microhemorrhage detected in Tg2576 mice
immunized with mannan-Aβ28 may be anti-Aβ antibody
binding to Aβ in cerebral vasculature. If so, one potential
culprit in the microhemorrhage may be the activation of
the complement cascade by antibody-Aβ immune com-
plexes at sites of CAA [89,90]. Our data demonstrating
that C1q and C3b are found in the cortical brain sections
of mice immunized with mannan-Aβ28, but not control
animals (Figure 6A) indicate that binding of antibody-Aβ
to Aβ deposits in the cerebral vasculature may in fact
induce microhemorrhages. Of note, we demonstrated that
the level of decoration of ThS-stained vascular fibrillar Aβ
with complement components C1q (Figure 6B) and C3b
(data not shown) was highest in the meninges of mice
immunized with mannan-Aβ28. In this group, β-amyloid
deposits had altered morphology suggestive of ongoing
clearance, and were heavily decorated with C1q compo-
nent of complement. On the contrary, very small or prac-
tically absent C1q profiles were co-localized with
substantial and unaltered Aβ load of the meninges of BSA-
mannan-immunized or non-immunized groups, respec-
tively (Figure 6B). Importantly, recently it was shown that
microhemorrhages in PDAPP mice passively immunized
with the 3D6 antibody, being dose-responsive, co-local-
ized with the vascular amyloid accumulations having
altered Aβ morphology [62].
It is noteworthy that the microhemorrhages triggered by
anti-Aβ antibodies may play an important role in reduc-
tion of AD-like pathology, which we observed in aged
Tg2576 mice vaccinated with mannan-Aβ28. This seems
plausible, since only low concentrations of free anti-Aβ
antibodies were detected in the sera of vaccinated mice
after 11 months without further boosting with the man-
nan-Aβ28, and mannan-BSA did not induce microhemor-
rhages. Although we observed less total glial activation in
the brains of mice vaccinated with mannan-Aβ28than in
the brains of control animals (Figure 3), it is possible that
areas affected by microhemorrhages may have higher
CD45 and GFAP immunoreactivity. Future studies of the
underlying mechanisms responsible for the antibody-
induced microhemorrhages in mice may be useful for
avoiding these potentially adverse events in AD patients
receiving anti-Aβ immunotherapy.
Conclusion
Our novel vaccine candidate based on Aβ28 conjugated to
mannan, as the molecular adjuvant, induced production
of anti-Aβ antibodies in Tg2576 mice, which have been
shown to be hyporesponsive to immunization with Aβ
self antigen, in the absence of conventional adjuvant. As
expected, the mannan-Aβ28 conjugate induced the genera-
tion of Th2-type anti-Aβ antibodies, which significantly
attenuated amyloid deposition in old Tg2576 mice. How-
ever, there were increased levels of cerebral microhemor-
rhage in mannan-Aβ28 immunized mice, which did not
appear to be due to the anti-mannan antibody response
induced by the immunoconjugate, because mice immu-
nized with mannan-BSA generated higher titers of anti-
mannan antibodies than mice immunized with mannan-
Aβ28 and they did not show elevated levels of microhem-
orrhage. Whether the anti-mannan antibodies increasedPage 13 of 16
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of anti-Aβ antibodies entry into cerebral perivascular and
parenchymal spaces contributed to the increased inci-
dence of microhemorrhages remains to be investigated in
future studies.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IP helped perform the immunizations of mice, brain col-
lection and preparation of sections, immunohistochemi-
cal and histochemical analysis of brain sections and
drafted the manuscript. AG participated in the design of
the study, carried out blood collection, performed dot
blot analysis for characterization of anti-Aβ antibody and
helped to draft the manuscript. MM participated in the
design of study and performed the statistical analysis. GM
performed the quantification of staining using NIH image
1.59b5 software, conducted the ThS staining of brain sec-
tions. NM carried out ELISA for determination of anti-Aβ
and anti-mannan antibody. RA helped to immunize mice
and to prepare brain sections. VV analysed the activation
of C1q and C3b in the brains of mice. AK helped to ana-
lyze antibody responses and to prepare figures. AL carried
out the generation of mannan-Aβ28 and mannan-BSA
conjugates and helped in the penultimate version of the
manuscript. MGA conceived the study, helped in the
design of the experiments and assisted in the preparation
of the text and the figures in the manuscript. DHC con-
ceived the study, designed and coordinated the experi-
ments and helped in the drafting and editing of the
manuscript. He was responsible for the final version of the
manuscript. All authors read and approved the final man-
uscript.
Acknowledgements
Sources of Support: This work was supported by NIH grants: AG20241, 
AG000538 and NS50895 to DHC; NS057395 to MGA; to ; IIRG grants 
from the Alzheimer's Association: IIRG-03-6279 for MGA and DHC, and 
IIRG-07-28314 for AG and DHC.
References
1. Price DL, Sisodia SS: Cellular and molecular biology of Alzhe-
imer's disease and animal models.  Annu Rev Med 1994,
45:435-446.
2. Selkoe DJ: Amyloid protein and Alzheimer's disease.  Sci Am
1991, 265:68-71.
3. Selkoe DJ: Alzheimer's disease: a central role for amyloid.  J
Neuropath and Exp Neurology 1994, 53:438-447.
4. Esler WP, Wolfe MS: A Portrait of Alzheimer Secretases-New
Features and Familiar Faces.  Science 2001, 293:1449-1454.
5. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cas-
cade hypothesis.  Science 1992, 256:184-185.
6. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's dis-
ease: progress and problems on the road to therapeutics.  Sci-
ence 2002, 297:353-356.
7. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu
K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z,
Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N,
Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P:
Immunization with amyloid-beta attenuates Alzheimer-dis-
ease-like pathology in the PDAPP mouse [see comments].
Nature 1999, 400:173-177.
8. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J,
Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope
C, Gordon M, Arendash GW: A beta peptide vaccination pre-
vents memory loss in an animal model of Alzheimer's dis-
ease.  Nature 2000, 408:982-985.
9. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD,
Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mer-
cken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A
beta peptide immunization reduces behavioural impairment
and plaques in a model of Alzheimer's disease.  Nature 2000,
408:979-982.
10. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A,
McConlogue L, Games D, Freedman SB, Morris RGM: A learning
deficit related to age and beta-amyloid plaques in a mouse
model of Alzheimer's disease.  Nature 2000, 408:975-979.
11. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido
T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M,
Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K,
Welch B, Seubert P, Schenk D, Yednock T: Peripherally adminis-
tered antibodies against amyloid beta-peptide enter the cen-
tral nervous system and reduce pathology in a mouse model
of Alzheimer disease.  Nat Med 2000, 6:916-919.
12. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman
DM: Peripheral anti-A beta antibody alters CNS and plasma
A beta clearance and decreases brain A beta burden in a
mouse model of Alzheimer's disease.  Proc Natl Acad Sci USA
2001, 98:8850-8855.
13. Orgogozo JM, Gilman S, Dartigues JM, Laurent B, Puel M, Kirby LC,
Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank
A, Hock C: Subacute meningoencephalitis in a subset of
patients with AD after Abeta42 immunization.  Neurology
2003, 61(1):46-54.
14. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P,
Games D, Kirby L, Schenk D: Abeta vaccination effects on
plaque pathology in the absence of encephalitis in Alzheimer
disease.  Neurology 2005, 64:129-131.
15. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO:
Neuropathology of human Alzheimer disease after immuni-
zation with amyloid-beta peptide: a case report.  Nat Med
2003, 9:448-452.
16. Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F: Neuropa-
thology and pathogenesis of encephalitis following amyloid-
beta immunization in Alzheimer's disease.  Brain Pathol 2004,
14:11-20.
17. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A,
Pluchino S, Uccelli A, Comi G, Martino G: Vaccination with amy-
loid-beta peptide induces autoimmune encephalomyelitis in
C57/BL6 mice.  Brain 2003, 126:285-291.
18. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel
M, Mathews PM, Jucker M: Cerebral hemorrhage after passive
anti-Abeta immunotherapy.  Science 2002, 298:1379.
19. DeMattos RB, Boone LI, Hepburn DL, Parsadanian M, Bryan MT, Ness
DK, Piroozi KS, Holtzman DM, Bales KR, Gitter BD, Paul SM, Racke
M: In vitro and in vivo characterization of beta-amyloid anti-
bodies binding to cerebral amyloid angiopathy (CAA) and
the selective exacerbation of CAA-associated microhemor-
rhage.  Neurobiol Aging 2004, 25:577.
20. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gor-
don MN, Morgan D: Passive immunotherapy against Abeta in
aged APP-transgenic mice reverses cognitive deficits and
depletes parenchymal amyloid deposits in spite of increased
vascular amyloid and microhemorrhage.  J Neuroinflammation
2004, 1:24.
21. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J,
Ronan V, Symmonds K, Gordon MN, Morgan D: Deglycosylated
anti-amyloid-beta antibodies eliminate cognitive deficits and
reduce parenchymal amyloid with minimal vascular conse-
quences in aged amyloid precursor protein transgenic mice.
J Neurosci 2006, 26:5340-5346.
22. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN: Amyloid-b
vaccination, but not nitro-NSAID treatment, increases vas-
cular amyloid and microhemorrhage while both reduce
parenchymal amyloid.  Neuroscience 2007, 144:950-960.Page 14 of 16
(page number not for citation purposes)
Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/4223. Turner MW: Mannose-binding lectin: the pluripotent mole-
cule of the innate immune system.  Immunology Today 1996,
17:532-540.
24. Vasta GR, Quesenberry M, Ahmed H, O'Leary N: C-type lectins
and galectins mediate innate and adaptive immune func-
tions: their roles in the complement activation pathway.  Dev
Comp Immunol 1999, 23(4-5):401-420.
25. Tenner AJ: Membrane receptors for soluble defense collagens.
Current Opinion in Immunology 1999, 11:34-41.
26. Engering AJ, Cella M, Fluitsma DM, Hoefsmit EC, Lanzavecchia A, Pie-
ters J: Mannose receptor mediated antigen uptake and pres-
entation in human dendritic cells.  Advances in Experimental
Medicine and Biology 1997, 417:183-187.
27. Linehan SA, Martinez-Pomares L, Gordon S: Mannose receptor
and scavenger receptor: two macrophage pattern recogni-
tion receptors with diverse functions in tissue homeostasis
and host defense.  Adv Exp Med Biol 2000, 479:1-14.
28. Gröger M, Holnthoner W, Maurer D, Lechleitner S, Wolff K, Mayr
BB, Lubitz W, Petzelbauer P: Dermal microvascular endothelial
cells express the 180-kDa macrophage mannose receptor in
situ and in vitro.  J Immunol 2000, 165(10):5428-5434.
29. Galea I, Palin K, Newman TA, Van Rooijen N, Perry VH, Boche D:
Mannose receptor expression specifically reveals perivascu-
lar macrophages in normal, injured, and diseased mouse
brain.  Glia 2005, 49:375-384.
30. Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nichol-
son-Weller A: Complement receptor 1/CD35 is a receptor for
mannan-binding lectin.  Journal of Experimental Medicine 2000,
192:1797-1808.
31. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM: Cross-
linking CD21/CD35 or CD19 increases both B7-1 and B7-2
expression on murine splenic B cells.  J Immunol 1998,
160(4):1565-1572.
32. Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-
Schoenberger J, Karr RW, Chaplin DD: Markedly impaired
humoral immune response in mice deficient in complement
receptors 1 and 2.  Proceedings of the National Academy of Sciences of
the United States of America 1996, 93:3357-3361.
33. Okawa Y, Howard CR, Steward MW: Production of anti-peptide
specific antibody in mice following immunization with pep-
tides conjugated to mannan.  Journal of Immunological Methods
1992, 149:127-131.
34. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie
IF: Oxidative/reductive conjugation of mannan to antigen
selects for T1 or T2 immune responses.  Proceedings of the
National Academy of Sciences of the United States of America 1995,
92:10128-10132.
35. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IFC: Ex vivo
targeting of the macrophage mannose receptor generates
anti-tumor CTL responses.  Vaccine 2000, 18:3174-3184.
36. Fearon DT, Locksley RM: The instructive role of innate immu-
nity in the acquired immune response.  Science 1996,
272:50-53.
37. Apostolopoulos V, McKenzie IF: Role of the mannose receptor in
the immune response.  Curr Mol Med 2001, 1:469-474.
38. Vaughan HA, Ho DW, Karanikas VA, Ong CS, Hwang LA, Pearson JM,
McKenzie IF, Pietersz GA: Induction of humoral and cellular
responses in cynomolgus monkeys immunised with mannan-
human MUC1 conjugates.  Vaccine 1999, 17:2740-2752.
39. Ghochikyan A, Petrushina I, Lees A, Vasilevko V, Movsesyan N, Kar-
apetyan A, Agadjanyan MG, Cribbs DH: Ab-immunotherapy for
Alzheimer's disease using mannan-amyloid-beta peptide
immunoconjugates.  DNA and Cell Biology 2006, 25:571-580.
40. Lees A, Nelson BL, Mond JJ: Activation of soluble polysaccha-
rides with 1-cyano-4-dimethylaminopyridinium tetrafluor-
oborate for use in protein-polysaccharide conjugate vaccines
and immunological reagents.  Vaccine 1996, 14:190-198.
41. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang
F, Cole G: Correlative memory deficits, Aβ elevation, and
amyloid plaques in transgenic mice.  Science 1996, 274:99-102.
42. Frautschy SY F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM:
Microglial response to amyloid plaques in APPsw transgenic
mice.  American Journal of Pathology 1998, 152:307-317.
43. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher
M, Ashe KH: A specific amyloid-beta protein assembly in the
brain impairs memory.  Nature 2006, 440:352-357.
44. Cribbs DH, Ghochikyan A, Tran M, Vasilevko V, Petrushina I,
Sadzikava N, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan
MG: Adjuvant-dependent modulation of Th1 and Th2
responses to immunization with beta-amyloid.  Int Immunol
2003, 15:505-514.
45. Ghochikyan A, Vasilevko V, Petrushina I, Tran M, Sadzikava N,
Babikyan D, Movsesyan N, Tian W, Ross TM, Cribbs DH, Agadjanyan
MG: Generation and chracterization of the humoral immune
response to DNA immunization with a chimeric β-amyloid-
interleukin-4 minigene.  Eur J Immunol 2003, 33:3232-3241.
46. Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agad-
janyan MG, Cribbs DH: Importance of IgG2c isotype in the
immune response to b-amyloid in APP/Tg mice.  Neurosci Let-
ters 2003, 338:5-8.
47. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina
I, Movsesyan N, Mina E, Kiyatkin A, Glabe C, Cribbs DH, Agadjanyan
MG: Anti-Abeta 1–11 antibody binds to different beta-amy-
loid species, inhibits fibril formation, and disaggregates pre-
formed fibrils, but not the most toxic oligomers.  J Biol Chem
2007, 282:22376-22386.
48. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman
CW, Glabe CG: Common structure of soluble amyloid oli-
gomers implies common mechanism of pathogenesis.  Science
2003, 300:486-489.
49. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movse-
syan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG:
Alzheimer's Disease Peptide Epitope Vaccine Reduces Insol-
uble But Not Soluble/Oligomeric A{beta} Species in Amy-
loid Precursor Protein Transgenic Mice.  J Neurosci 2007,
27:12721-12731.
50. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H,
Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG:
Reducing AD-like pathology in 3xTg-AD mouse model by
DNA epitope vaccine- a novel immunotherapeutic strategy.
PLoS ONE 2008, 3(5):e2124.
51. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold
KH, Tolnay M, Staufenbiel M, Jucker M: Spontaneous hemor-
rhagic stroke in a mouse model of cerebral amyloid angiop-
athy.  J Neurosci 2001, 21:1619-1627.
52. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH:
Complement Association with Neurons and B-Amyloid
Deposition in the Brains of Aged Individuals with Down Syn-
drome.  Neurobiology of Disease 2001, 8:252-265.
53. Finkelman FD, Holmes J, Katona IM, Urban JF, Beckmann MP, Park LS,
Schooley KA, Coffman RL, Mossmann TR, Paul WE: Lymphokine
control of in vivo immunoglobulin isotype selection.  Annu Rev
Immunol 1990, 8:303-333.
54. Chauhan NB, Siegel GJ: Efficacy of anti-Abeta antibody isotypes
used for intracerebroventricular immunization in
TgCRND8.  Neurosci Lett 2005, 375:143-147.
55. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM: Dynamic
complexity of the microglial activation response in trans-
genic models of amyloid deposition: implications for Alzhe-
imer therapeutics.  J Neuropathol Exp Neurol 2005, 64:743-753.
56. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE,
Gordon MN, Morgan D: Intracranially administered anti-Abeta
antibodies reduce beta-amyloid deposition by mechanisms
both independent of and associated with microglial activa-
tion.  J Neurosci 2003, 23:3745-3751.
57. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN,
Morgan D: Microglial activation facilitates Abeta plaque
removal following intracranial anti-Abeta antibody adminis-
tration.  Neurobiol Dis 2004, 15:11-20.
58. Chung H, Brazil MI, Soe TT, Maxfield FR: Uptake, degradation,
and release of fibrillar and soluble forms of Alzheimer's amy-
loid beta-peptide by microglial cells.  J Biol Chem 1999,
274:32301-32308.
59. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: Bone marrow-
derived microglia play a critical role in restricting senile
plaque formation in Alzheimer's disease.  Neuron 2006,
49:489-502.
60. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C,
DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization
reverses memory deficits without reducing brain Abeta bur-
den in Alzheimer's disease model.  Nat Neurosci 2002,
5:452-457.Page 15 of 16
(page number not for citation purposes)
Journal of Neuroinflammation 2008, 5:42 http://www.jneuroinflammation.com/content/5/1/42Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
61. Frenkel D, Maron R, Burt DS, Weiner HL: Nasal vaccination with
a proteosome-based adjuvant and glatiramer acetate clears
beta-amyloid in a mouse model of Alzheimer disease.  J Clin
Invest 2005, 115:2423-2433.
62. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D,
Basi G, Schenk D, Seubert P, Games D: Immunotherapy reduces
vascular amyloid-beta in PDAPP mice.  J Neurosci 2008,
28:6787-6793.
63. Schenk D: Opinion: Amyloid-beta immunotherapy for Alzhe-
imer's disease: the end of the beginning.  Nat Rev Neurosci 2002,
3:824-828.
64. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D,
Hyman BT: Non-Fc-mediated mechanisms are involved in
clearance of amyloid-beta in vivo by immunotherapy.  J Neu-
rosci 2002, 22:7873-7878.
65. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L,
Hyman BT, Younkin S, Ashe KH: Reversible memory loss in a
mouse transgenic model of Alzheimer's disease.  J Neurosci
2002, 22:6331-6335.
66. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L,
Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of
Abeta immunization (AN1792) in patients with AD in an
interrupted trial.  Neurology 2005, 64:1553-1562.
67. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L,
Millais SB, Donoghue S: Evaluation of the safety and immuno-
genicity of synthetic Abeta42 (AN1792) in patients with AD.
Neurology 2005, 64:94-101.
68. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs
DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach
TG, Castano EM, Roher AE: Amyloid-beta peptide remnants in
AN-1792-immunized Alzheimer's disease patients: a bio-
chemical analysis.  Am J Pathol 2006, 169:1048-1063.
69. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vla-
chouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Hol-
mes C: Abeta species removal after abeta42 immunization.  J
Neuropathol Exp Neurol 2006, 65:1040-1048.
70. Engering AJ, Cella M, Fluitsma D, Brockhaus M, Hoefsmit EC, Lanza-
vecchia A, Pieters J: The mannose receptor functions as a high
capacity and broad specificity antigen receptor in human
dendritic cells.  Eur J Immunol 1997, 27:2417-2425.
71. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V,
Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R,
Thynne G, McKenzie IFC: Antibody and T cell responses of
patients with adenocarcinoma immunized with mannan-
MUC1 fusion protein.  Journal of Clinical Investigation 1997,
100:2783-2792.
72. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey
TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod
KS, Doherty PC, Hurwitz JL: Long lived multi-isotype anti-HIV
antibody responses following a prime-double boost immuni-
zation strategy.  Vaccine 2005, 23:2454-2464.
73. Stambas J, Pietersz G, McKenzie I, Cheers C: Oxidised mannan as
a novel adjuvant inducing mucosal IgA production.  Vaccine
2002, 20:1068-1078.
74. Stambas J, Pietersz G, McKenzie I, Nagabhushanam V, Cheers C: Oxi-
dised mannan-listeriolysin O conjugates induce Th1/Th2
cytokine responses after intranasal immunisation.  Vaccine
2002, 20:1877-1886.
75. Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz
GA: The immune response of mice and cynomolgus monkeys
to macaque mucin 1-mannan.  Vaccine 2000, 18:3297-3309.
76. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW,
Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: Dimeric
amyloid beta protein rapidly accumulates in lipid rafts fol-
lowed by apolipoprotein E and phosphorylated tau accumu-
lation in the Tg2576 mouse model of Alzheimer's disease.  J
Neurosci 2004, 24:3801-3809.
77. Das P, Chapoval S, Howard V, David CS, Golde TE: Immune
responses against Abeta1–42 in HLA class II transgenic mice:
implications for Abeta1–42 immune-mediated therapies.
Neurobiol Aging 2003, 24:969-976.
78. Lemere C, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone
JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements
JD, Selkoe DJ, Duff K: Evidence for peripheral clearance of cer-
ebral Abeta protein following chronic, active Abeta immuni-
zation in PSAPP mice.  Neurobiol Dis 2003, 14(1):10-18.
79. Lemere CA, Spooner ET, Leverone JF, Mori C, Iglesias M, Bloom JK,
Seabrook TJ: Amyloid-beta immunization in Alzheimer's dis-
ease transgenic mouse models and wildtype mice.  Neurochem
Res 2003, 28:1017-1027.
80. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman
A: Cerebral amyloid angiopathy in the brains of patients with
Alzheimer's disease: the CERAD experience, Part XV.  Neu-
rology 1996, 46:1592-1596.
81. Tian J, Shi J, Mann DM: Cerebral amyloid angiopathy and
dementia.  Panminerva Med 2004, 46:253-264.
82. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM,
Holtzman DM: Human apolipoprotein E4 alters the amyloid-
beta 40:42 ratio and promotes the formation of cerebral
amyloid angiopathy in an amyloid precursor protein trans-
genic model.  J Neurosci 2005, 25:2803-2810.
83. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM,
Bales K, Ashe KH, Irizarry MC, Hyman BT: Apolipoprotein E facil-
itates neuritic and cerebrovascular plaque formation in an
Alzheimer's disease model.  Ann Neurol 2000, 47:739-747.
84. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness
DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman
DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB: Exacer-
bation of cerebral amyloid angiopathy-associated microhe-
morrhage in amyloid precursor protein transgenic mice by
immunotherapy is dependent on antibody recognition of
deposited forms of amyloid beta.  J Neurosci 2005, 25:629-636.
85. Lee EB, Leng LZ, Lee VM, Trojanowski JQ: Meningoencephalitis
associated with passive immunization of a transgenic murine
model of Alzheimer's amyloidosis.  FEBS Lett 2005,
579:2564-2568.
86. Miao J, Vitek MP, Xu F, Previti ML, Davis J, Van Nostrand WE: Reduc-
ing cerebral microvascular amyloid-beta protein deposition
diminishes regional neuroinflammation in vasculotropic
mutant amyloid precursor protein transgenic mice.  J Neurosci
2005, 25:6271-6277.
87. Herzig MC, Van Nostrand WE, Jucker M: Mechanism of cerebral
beta-amyloid angiopathy: murine and cellular models.  Brain
Pathol 2006, 16:40-54.
88. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M,
Holtzman DM: Apolipoprotein E markedly facilitates age-
dependent cerebral amyloid angiopathy and spontaneous
hemorrhage in amyloid precursor protein transgenic mice.  J
Neurosci 2003, 23:7889-7896.
89. Eikelenboom P, Stam FC: Immunoglobulins and complement
factors in senile plaques. An immunoperoxidase study.  Acta
Neuropathol 1982, 57:239-242.
90. Eikelenboom P, Veerhuis R: The role of complement and acti-
vated microglia in the pathogenesis of Alzheimer's disease.
Neurobiol Aging 1996, 17:673-680.Page 16 of 16
(page number not for citation purposes)
